Skip to main content
Top
Published in: African Journal of Urology 1/2024

Open Access 01-12-2024 | Neuropathic Pain | Original Research

Assessment of neuropathic pain management knowledge, attitudes, and practices among urology trainees and consultants in prostate cancer care: a survey-based study

Authors: O. Sinkila, N. Matjomane, T. Cronje, K. Mathabe

Published in: African Journal of Urology | Issue 1/2024

Login to get access

Abstract

Background

Effective neuropathic pain management is crucial in improving the quality of life for patients with prostate cancer. There is an abundance of research about cancer pain and guidelines that have been developed by World Health Organization including the analgesia stepladder, yet patients with cancer pain are still sub optimally analgesed. This is due to a variety of both patient and physician factors which include: lack of knowledge on the use of adjuvant medication, fear of addiction and poor characterization of the type of pain. This study intended to assess the knowledge, attitudes, and practices of urology trainees and consultants in the the context of neuropathic pain in prostatecancer care.

Methods

The study involved 91 urologists, comprising of junior registrars, medical officers and experienced specialists who are members of the South African Urological Association (SAUA). Data was collected through a 25-question web-based survey. The survey covered: demographic information, knowledge, attitudes, and practices related to cancer pain management.

Results

The study revealed that a significant proportion of urologists assessed neuropathic pain reactively, with only 8% of respondents being familiar with screening scales. Approximately, one-third preferred referrals, and 74% expressed confidence in self-treatment. Concerns regarding opioid prescription were observed in 40.4% of respondents. Furthermore, the usage of adjuvant medications was limited, with only 35% proficiently combining analgesia and adjuvants. Notably, 65% continued to escalate analgesic monotherapy.

Conclusion

Effective neuropathic pain management in prostate cancer care necessitates a multidisciplinary approach, comprehensive assessment and expertise in adjuvant medication usage. The discrepancies observed among urologists are likely due to variations in experience levels. The study identifies knowledge gaps and suboptimal practices in neuropathic pain management among urologists. Addressing these issues through education, awareness, and interdisciplinary collaboration is imperative to enhance patient outcomes and improve the quality of life for individuals with prostate cancer. This study underscores the need for improved education and interdisciplinary collaboration among urologists in managing neuropathic pain among prostate cancer patients. Enhancing these aspects is essential to achieve better patient outcomes and overall quality of life.
Literature
1.
go back to reference Mason RJ et al (2022) UPDATE—2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis: endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging. Can Urol Assoc J 16(4):184–196CrossRef Mason RJ et al (2022) UPDATE—2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis: endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging. Can Urol Assoc J 16(4):184–196CrossRef
2.
go back to reference Canadian Cancer Society's Advisory Committee on Cancer Statistics (2015) Canadian cancer statistics 2015-special topic: predictions of the future burden of cancer in Canada. Canadian Cancer Society, Toronto Canadian Cancer Society's Advisory Committee on Cancer Statistics (2015) Canadian cancer statistics 2015-special topic: predictions of the future burden of cancer in Canada. Canadian Cancer Society, Toronto
3.
go back to reference Jost L, ESMO Guidelines Working Group (2007) Management of cancer pain: ESMO clinical recommendations. Ann Oncol 18:92–94CrossRef Jost L, ESMO Guidelines Working Group (2007) Management of cancer pain: ESMO clinical recommendations. Ann Oncol 18:92–94CrossRef
4.
go back to reference Keefe FJ, Abernethy AP, Campbell LC (2005) Psychological approaches to understanding and treating disease-related pain. Ann Rev Psychol 56:601–630CrossRef Keefe FJ, Abernethy AP, Campbell LC (2005) Psychological approaches to understanding and treating disease-related pain. Ann Rev Psychol 56:601–630CrossRef
5.
6.
go back to reference Money S, Garber B (2018) Management of cancer pain. Curr Emerg Hosp Med Rep 6(4):141–146CrossRef Money S, Garber B (2018) Management of cancer pain. Curr Emerg Hosp Med Rep 6(4):141–146CrossRef
7.
go back to reference Alleaume C et al (2018) Chronic neuropathic pain negatively associated with employment retention of cancer survivors: evidence from a national French survey. J Cancer Surviv Res Pract 12(1):115–126CrossRef Alleaume C et al (2018) Chronic neuropathic pain negatively associated with employment retention of cancer survivors: evidence from a national French survey. J Cancer Surviv Res Pract 12(1):115–126CrossRef
8.
go back to reference Meyer-Rosberg K et al (2001) Peripheral neuropathic pain—a multidimensional burden for patients. Eur J Pain 5(4):379–389PubMedCrossRef Meyer-Rosberg K et al (2001) Peripheral neuropathic pain—a multidimensional burden for patients. Eur J Pain 5(4):379–389PubMedCrossRef
9.
go back to reference Bouhassira D et al (2008) Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 136(3):380–387PubMedCrossRef Bouhassira D et al (2008) Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 136(3):380–387PubMedCrossRef
10.
go back to reference Davis MP, Walsh D (2004) Epidemiology of cancer pain and factors influencing poor pain control. Am J Hosp Palliat Care 21(2):137–142PubMedCrossRef Davis MP, Walsh D (2004) Epidemiology of cancer pain and factors influencing poor pain control. Am J Hosp Palliat Care 21(2):137–142PubMedCrossRef
11.
go back to reference Wordliczek J, Zajaczkowska R (2013) Mechanisms in cancer pain. Springer-Verlag London Ltd., LondonCrossRef Wordliczek J, Zajaczkowska R (2013) Mechanisms in cancer pain. Springer-Verlag London Ltd., LondonCrossRef
12.
go back to reference Bennett MI et al (2012) Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain 153(2):359–365PubMedCrossRef Bennett MI et al (2012) Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain 153(2):359–365PubMedCrossRef
13.
14.
go back to reference Keskinbora KMD, Pekel AFMD, Aydinli IMD (2007) Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial. J Pain Symptom Manag 34(2):183–189CrossRef Keskinbora KMD, Pekel AFMD, Aydinli IMD (2007) Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial. J Pain Symptom Manag 34(2):183–189CrossRef
15.
go back to reference National Institute for Clinical Excellence (2004) Improving supportive and palliative care for adults with cancer: executive summary. National Institute for Clinical Excellence, London National Institute for Clinical Excellence (2004) Improving supportive and palliative care for adults with cancer: executive summary. National Institute for Clinical Excellence, London
16.
go back to reference Jadad AR, Browman GP (1995) The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 274(23):1870–1873PubMedCrossRef Jadad AR, Browman GP (1995) The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 274(23):1870–1873PubMedCrossRef
17.
go back to reference Zech DFJ et al (1995) Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 63(1):65–76PubMedCrossRef Zech DFJ et al (1995) Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 63(1):65–76PubMedCrossRef
18.
go back to reference Mercadante S (1999) Pain treatment and outcomes for patients with advanced cancer who receive follow-up care at home. Cancer 85(8):1849–1858PubMedCrossRef Mercadante S (1999) Pain treatment and outcomes for patients with advanced cancer who receive follow-up care at home. Cancer 85(8):1849–1858PubMedCrossRef
19.
go back to reference Pérez C et al (2015) Prevalence of pain and relative diagnostic performance of screening tools for neuropathic pain in cancer patients: a cross-sectional study. Eur J Pain 19(6):752–761PubMedCrossRef Pérez C et al (2015) Prevalence of pain and relative diagnostic performance of screening tools for neuropathic pain in cancer patients: a cross-sectional study. Eur J Pain 19(6):752–761PubMedCrossRef
20.
go back to reference George, B., et al. Opioids in cancer-related pain: current situation and outlook. Supportive care in cancer, 2019. George, B., et al. Opioids in cancer-related pain: current situation and outlook. Supportive care in cancer, 2019.
21.
go back to reference Azevedo São Leão Ferreira K, Kimura M, Jacobsen Teixeira M (2006) The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it? Support Care Cancer 14:1086–1093PubMedCrossRef Azevedo São Leão Ferreira K, Kimura M, Jacobsen Teixeira M (2006) The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it? Support Care Cancer 14:1086–1093PubMedCrossRef
22.
go back to reference Vranken MJM et al (2017) Barriers to access to opioid medicines for patients with opioid dependence: a review of legislation and regulations in eleven central and eastern European countries. Addiction 112(6):1069–1076PubMedCrossRef Vranken MJM et al (2017) Barriers to access to opioid medicines for patients with opioid dependence: a review of legislation and regulations in eleven central and eastern European countries. Addiction 112(6):1069–1076PubMedCrossRef
23.
go back to reference Minello C et al (2019) Assessing cancer pain—the first step toward improving patients’ quality of life. Support Care Cancer 27(8):3095–3104PubMedCrossRef Minello C et al (2019) Assessing cancer pain—the first step toward improving patients’ quality of life. Support Care Cancer 27(8):3095–3104PubMedCrossRef
24.
go back to reference Højsted J, Sjøgren P (2007) Addiction to opioids in chronic pain patients: a literature review. Eur J Pain 11(5):490–518PubMedCrossRef Højsted J, Sjøgren P (2007) Addiction to opioids in chronic pain patients: a literature review. Eur J Pain 11(5):490–518PubMedCrossRef
25.
go back to reference Aho T et al (2020) Douleur Neuropathique 4 (DN4) stratifies possible and definite neuropathic pain after surgical peripheral nerve lesion. Eur J Pain 24(2):413–422PubMedCrossRef Aho T et al (2020) Douleur Neuropathique 4 (DN4) stratifies possible and definite neuropathic pain after surgical peripheral nerve lesion. Eur J Pain 24(2):413–422PubMedCrossRef
26.
go back to reference Gudala K, Ghai B, Bansal D (2017) Neuropathic pain assessment with the PainDETECT questionnaire: cross-cultural adaptation and psychometric evaluation to Hindi. Pain Pract 17(8):1042–1049PubMedCrossRef Gudala K, Ghai B, Bansal D (2017) Neuropathic pain assessment with the PainDETECT questionnaire: cross-cultural adaptation and psychometric evaluation to Hindi. Pain Pract 17(8):1042–1049PubMedCrossRef
27.
go back to reference Mathieson S et al (2015) Neuropathic pain screening questionnaires have limited measurement properties. A systematic review. J Clin Epidemiol 68(8):957–966PubMedCrossRef Mathieson S et al (2015) Neuropathic pain screening questionnaires have limited measurement properties. A systematic review. J Clin Epidemiol 68(8):957–966PubMedCrossRef
28.
go back to reference VanDenKerkhof EG et al (2018) Sensitivity of the DN4 in screening for neuropathic pain syndromes. Clin J Pain 34(1):30–36PubMedCrossRef VanDenKerkhof EG et al (2018) Sensitivity of the DN4 in screening for neuropathic pain syndromes. Clin J Pain 34(1):30–36PubMedCrossRef
29.
go back to reference Attal N, Bouhassira D, Baron R (2018) Diagnosis and assessment of neuropathic pain through questionnaires. Lancet Neurol 17(5):456–466PubMedCrossRef Attal N, Bouhassira D, Baron R (2018) Diagnosis and assessment of neuropathic pain through questionnaires. Lancet Neurol 17(5):456–466PubMedCrossRef
30.
go back to reference Bouhassira D et al (2005) Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 114(12):29–36PubMedCrossRef Bouhassira D et al (2005) Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 114(12):29–36PubMedCrossRef
31.
go back to reference Caraceni A et al (2004) Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 22(14):2909–2917PubMedCrossRef Caraceni A et al (2004) Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 22(14):2909–2917PubMedCrossRef
32.
go back to reference Rayment C et al (2013) Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative-Computerised Symptom Assessment study. Palliat Med 27(8):714–721PubMedCrossRef Rayment C et al (2013) Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative-Computerised Symptom Assessment study. Palliat Med 27(8):714–721PubMedCrossRef
33.
go back to reference Bennett MI (2011) Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med 25(5):553–559PubMedCrossRef Bennett MI (2011) Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med 25(5):553–559PubMedCrossRef
34.
go back to reference Mishra S et al (2012) A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Care 29(3):177–182PubMedCrossRef Mishra S et al (2012) A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Care 29(3):177–182PubMedCrossRef
35.
go back to reference Gunnarsdottir S et al (2002) Patient-related barriers to pain management: the Barriers Questionnaire II (BQ-II). Pain 99(3):385–396PubMedCrossRef Gunnarsdottir S et al (2002) Patient-related barriers to pain management: the Barriers Questionnaire II (BQ-II). Pain 99(3):385–396PubMedCrossRef
36.
go back to reference Chou R, Clark E, Helfand M (2003) Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manage 26(5):1026–1048PubMedCrossRef Chou R, Clark E, Helfand M (2003) Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manage 26(5):1026–1048PubMedCrossRef
37.
38.
go back to reference Gunnarsdottir S et al (2017) A multicenter study of attitudinal barriers to cancer pain management. Support Care Cancer 25(11):3595–3602PubMedCrossRef Gunnarsdottir S et al (2017) A multicenter study of attitudinal barriers to cancer pain management. Support Care Cancer 25(11):3595–3602PubMedCrossRef
39.
go back to reference Yennurajalingam S et al (2012) The impact of an outpatient palliative care consultation on symptom burden in advanced prostate cancer patients. J Palliat Med 15(1):20–24PubMedCrossRef Yennurajalingam S et al (2012) The impact of an outpatient palliative care consultation on symptom burden in advanced prostate cancer patients. J Palliat Med 15(1):20–24PubMedCrossRef
40.
go back to reference Carlson CL (2016) Effectiveness of the World Health Organization Cancer Pain Relief Guidelines: an integrative review. J Pain Res 2016:515–534CrossRef Carlson CL (2016) Effectiveness of the World Health Organization Cancer Pain Relief Guidelines: an integrative review. J Pain Res 2016:515–534CrossRef
41.
go back to reference Breivik H et al (2009) Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 20(8):1420–1433PubMedCrossRef Breivik H et al (2009) Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 20(8):1420–1433PubMedCrossRef
42.
go back to reference Grond S et al (1999) Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain 79(1):15–20PubMedCrossRef Grond S et al (1999) Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain 79(1):15–20PubMedCrossRef
43.
go back to reference Virgen CG et al (2022) Pharmacological management of cancer pain: novel therapeutics. Biomed Pharmacother 156:113871PubMedCrossRef Virgen CG et al (2022) Pharmacological management of cancer pain: novel therapeutics. Biomed Pharmacother 156:113871PubMedCrossRef
Metadata
Title
Assessment of neuropathic pain management knowledge, attitudes, and practices among urology trainees and consultants in prostate cancer care: a survey-based study
Authors
O. Sinkila
N. Matjomane
T. Cronje
K. Mathabe
Publication date
01-12-2024
Publisher
Springer Berlin Heidelberg
Published in
African Journal of Urology / Issue 1/2024
Print ISSN: 1110-5704
Electronic ISSN: 1961-9987
DOI
https://doi.org/10.1186/s12301-024-00424-3

Other articles of this Issue 1/2024

African Journal of Urology 1/2024 Go to the issue